Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 8/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23792418 | 0.82 | NR1D1 (0.45) | TAAR1SLC6A2KDM4EALDH1A1 | |
| SCHEMBL13995625 | 0.81 | SIGMAR1 (0.47) | OPRK1OPRD1OPRM1SLC6A2KDM4E | |
| SCHEMBL2483550 | 0.72 | HDAC1 (0.55) | OPRK1OPRM1TAAR1SLC6A2ESR1 | |
| SCHEMBL23792428 | 0.72 | HTR1A (0.40) | OPRK1OPRD1OPRM1TAAR1KDM4E | |
| SCHEMBL3455752 | 0.70 | LPAR1 (0.57) | — | |
| SCHEMBL23792414 | 0.70 | TSHR (0.55) | OPRK1OPRD1OPRM1TAAR1KDM4E | |
| SCHEMBL104626 | 0.70 | ESR1 (0.59) | OPRK1OPRM1TAAR1SLC6A2KDM4E | |
| SCHEMBL6883532 | 0.69 | OPRM1 (0.41) | OPRK1OPRD1OPRM1TAAR1SLC6A2 | |
| SCHEMBL12039789 | 0.68 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL7543628 | 0.68 | KDM4E (0.48) | OPRK1OPRD1OPRM1TAAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | OPRK1 3949/4885OPRD1 4345/4885OPRM1 4223/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | OPRK1 3949/4885OPRD1 4345/4885OPRM1 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.